In the present study, we investigated the effects of micro-injecting 2-chloroadenosine (2-CADO; an adenosine receptor agonist) into the thalamus alone and with theophylline (a nonspecific adenosine receptor antagonist) pretreatment on pentylenetetrazol (PTZ)-induced tonic-clonic seizures in male Wistar albino rats. Following intrathalamic 2-CADO injection alone or theophylline pretreatment, 50 mg kg–1 PTZ was given ip after 1 and 24 hrs. The duration of epileptic seizure activity was recorded by cortical electroencephalogram (EEG), and seizure severity was behaviorally scored. Intrathalamic 2-CADO administration induced significant decreases in both seizure duration and seizure severity scores at 1 and 24 hrs, but the effects were more abundant on the seizures induced after 24 hrs. On the other hand, pretreatment with theophylline prevented the inhibitor effect of 2-CADO on seizure activity and increased both seizure duration and seizure scores. Present results suggest that the activation of adenosine receptors in the thalamus may represent another anticonvulsant/modulatory site of adenosine action during the course of the PTZ-induced generalized tonic-clonic seizures and provide additional data for the involvement of the adenosinergic system in the generalized seizures model.
HerbergLJ, RoseIC, MintzM. Effect of an adenosine A1 agonist injected into substantia nigra on kindling of epileptic seizures and convulsion duration. Pharmacol Biochem Behav44: 113–117, 1993.
6.
MalhotraJ, GuptaYK. Effect of adenosine receptor modulation on pentylenetetrazole-induced seizures in rats. Br J Pharmacol120: 282–288, 1997.
7.
GouderN, FritschyJM, BoisonD. Seizure suppression by adenosine A1 receptor activation in a mouse model of pharmacoresistant epilepsy. Epilepsia44: 877–885, 2003.
8.
YaarR, JonesMR, ChenJF, RavidK. Animal models for the study of adenosine receptor function. J Cell Physiol202: 9–20, 2005.
ReppertSM, WeaverDR, StehleJH, RivkeesSA. Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. Mol Endocrinol5: 1037–1048, 1991.
11.
DixonAK, GubitzAK, SirinathsinghjiDJ, RichardsonPJ, FreemanTC. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol118: 1461–1468, 1996.
12.
DavalJL, NicolasF, DoriatJF. Adenosine physiology and pharmacology: how about A2 receptors?Pharmacol Ther71: 325–335, 1996.
13.
DoriatJF, KozielV, HumbertAC, DavalJL. Medium- and long-term alterations of brain A1 and A2A adenosine receptor characteristics following repeated seizures in developing rats. Epilepsy Res35: 219–228, 1999.
14.
DoriatJF, KozielV, HumbertAC, DavalJL. Medium- and long-term effects of repeated bicuculline-induced seizures in developing rats on local cerebral energy metabolism. Brain Res800: 114–124, 1998.
15.
PagonopoulouO, AngelatouF, KostopoulosG. Effect of pentylentetrazol-induced seizures on A1 adenosine receptor regional density in the mouse brain: a quantitative autoradiographic study. Neuroscience56: 711–716, 1993.
16.
MillerJW, HallCM, HollandKD, FerrendelliJA. Identification of a median thalamic system regulating seizures and arousal. Epilepsia30: 493–500, 1989.
VelisekL, KubovaH, PohlM, StankovaL, MaresP, SchickerovaR. Pentylenetetrazol-induced seizures in rats: an ontogenetic study. Naunyn Schmiedebergs Arch Pharmacol346: 588–591, 1992.
21.
MirskiMA, RossellLA, TerryJB, FisherRS. Anticonvulsant effect of anterior thalamic high frequency electrical stimulation in the rat. Epilepsy Res28: 89–100, 1997.
22.
PagonopoulouO, AngelatouF, KostopoulosG. Effect of pentylentetrazol-induced seizures on A1 adenosine receptor regional density in the mouse brain: a quantitative autoradiographic study. Neuroscience56: 711–716, 1993.
23.
WinnHR, WelsiiJE, BrynerC, RubioR, BerneRM. Brain adenosine production during the initial 60 seconds of bicuculline seizures in rats. Acta Neurol Scand60: 536–537, 1979.
24.
DunwiddieTV, WorthT. Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. J Pharmacol Exp Ther220: 70–76, 1982.
25.
FredholmBB. Adenosine and neuroprotection. Int Rev Neurobiol40: 259–280, 1997.
26.
DichterMA. Emerging insights into mechanisms of epilepsy: implications for new antiepileptic drug development. Epilepsia35(Suppl 4):51–57, 1994.
27.
IlbayG, SahinD, KarsonA, AtesN. Effects of adenosine administration on spike-wave discharge frequency in genetically epileptic rats. Clin Exp Pharmacol Physiol28: 643–646, 2001.
28.
VarmaMR, DixonCE, JacksonEK, PetersGW, MelickJA, GriffithRP, VagniVA, ClarkRS, JenkinsLW, KochanekPM. Administration of adenosine receptor agonists or antagonists after controlled cortical impact in mice: effects on function and histopathology. Brain Res951: 191–201, 2002.
De SarroA, GrassoS, ZappalaM, NavaF, De SarroG. Convulsant effects of some xanthine derivatives in genetically epilepsy-prone rats. Naunyn Schmiedebergs Arch Pharmocol356: 48–55, 1997.
31.
GuptaYK, ChaudharyG, SrivastavaAK. Protective effect of resveratrol against pentylenetetrazole-induced seizures and its modulation by an adenosinergic system. Pharmacology65: 170–174, 2002
32.
ZagnoniPG, BianchiA, ZoloP, CangerR, CornaggiaC, D'alessandroP, DeMarcoP, PisaniF, GianelliM, VerzeL. Allopurinal as add-on therapy in refractory epilepsy: a double-blind placebo-controlled randomized study. Epilepsia35: 107–112, 1994
33.
Parada-TurskaJ, CzuczwarM, KisJ, CzuczwarP, CioczekA, LuszczkiJ, CzuczwarSJ. Allopurinal does not affect the anticonvulsant activity of carbamazepine and valproate in maximal electroshock-induced convulsions in mice. Pol J Pharmacol56: 67–72, 2004
34.
BorowiczKK, LuszczkiJ, CzuczwarSJ. 2-Chloroadenosine, a preferential agonist of adenosine A1 receptors, enhances the anticonvulsant activity of carbamazepine and clonazepam in mice. Eur Neuropsychopharmacol12: 173–179, 2002.
